AI Enabled Speech Therapy & Clinical Services Platform in Northern California

Why It Matters

The deal provides a rare entry into a high‑margin, AI‑enabled health‑tech niche with established clinical relationships and scalable intellectual property, positioning buyers to capture growing demand for digital speech‑therapy solutions.

Key Takeaways

• AI-driven speech assessment tools backed by $2.28M grants
• 2023 revenue surpassed $1M, EBITDA margin above 44%
• 2025 loss stemmed from $255k discretionary R&D spend
• 2026 client base rebounded to 366 active users
• Sale includes tech IP and profitable clinical services

Pulse Analysis

The convergence of artificial intelligence and speech‑language pathology is reshaping how clinicians assess and treat communication disorders. Platforms that embed AI algorithms into HIPAA‑ and FERPA‑compliant environments can deliver faster, data‑rich evaluations, especially for autism interventions where early detection is critical. By leveraging a proprietary dataset built through federal grants, the Northern California business not only reduces assessment time but also creates a defensible moat against generic tele‑therapy solutions.

Financially, the operation demonstrates the resilience of a hybrid model that pairs technology licensing with direct service revenue. After reaching a peak of $1.0 million in 2023, the company weathered a temporary contraction in 2025 caused by the loss of a Kaiser Permanente contract and a one‑off R&D outlay. Strategic cost cuts have slashed development expenses by more than 75%, and a new distribution partnership is set to expand market reach, positioning 2026 revenue between $847 k and $1.45 million with EBITDA margins potentially exceeding 50 percent. This trajectory underscores the scalability of the platform once the client pipeline stabilizes.

For prospective acquirers, the opportunity blends a cash‑generating clinical practice with a high‑growth technology asset. Valuation will likely reflect a multiple on the clinical EBITDA alongside a premium for the AI IP, its grant‑backed development history, and the untapped commercialization potential in schools and health systems nationwide. With no debt on the balance sheet and sellers offering transition support, the deal offers a turnkey entry into a fast‑evolving segment of digital health, where regulatory compliance and proven clinical outcomes are paramount for sustained expansion.